What it is
Prostamax is a cytomedin, or short peptide bioregulator, designed to support the function and regeneration of the prostate — the gland below the bladder in men that produces part of the fluid in semen and that commonly enlarges with age.
Bioregulators are peptides, meaning chains of amino acids, but much shorter than the ones on most of this site. That small size lowers the chance of the immune system treating them as a threat and mounting an unwanted response.
They also work in a different place. A standard peptide signals to a cell from outside, and the effect disappears once the peptide has cleared. A bioregulator is tied to one particular tissue, binds to DNA inside that tissue's cells, and changes which genes are running there. Because those genes govern repair, regeneration, and ageing, the effects are described as more foundational and longer-lasting than a peptide's. A plainer image: think of bioregulators as the body's reset switch.
Prostamax's tissue is the prostate. It is used for supporting prostate function in ageing men, addressing benign prostatic hyperplasia — an enlarged prostate that is not cancer, usually shortened to BPH — by easing its common symptoms such as needing to urinate more often, helping normalise male reproductive and sexual health, and helping restore urinary function affected by prostate enlargement.
It comes as a dry powder in a 20 milligram vial, mixed with bacteriostatic water and injected just under the skin.
Prostamax is a cytomedin-class short peptide bioregulator directed at the prostate gland, positioned for functional support and regeneration of prostatic tissue.
This page closes its class description with a figure the sibling pages do not use: bioregulators as the body's reset switch. That image is doing the work of the underlying argument, which runs as follows. Being shorter than conventional peptides, they give the immune system less to object to. Being tissue-specific, each reaches one organ — here the prostate. And rather than signalling to a prostate cell from outside, where the instruction lapses as the molecule clears, the compound is described as binding DNA within the cell and resetting which genes that cell runs. Since those genes govern repair, regeneration, and longevity, the reset is claimed to hold after dosing stops. No gene target is named, and no binding evidence is offered for any of it.
Stated uses: support of prostate function in ageing men; management of benign prostatic hyperplasia by mitigating its symptoms, urinary frequency named specifically; normalisation of male reproductive and sexual health; restoration of urinary function affected by prostatic enlargement.
Two structural points about this page are worth flagging before the detail. First, its "possible side effects" heading contains two interaction items rather than adverse effects — androgen therapy and prostate medications, and synergy with other bioregulators — which are handled in the avoidance section here rather than reproduced as side effects. Second, its contraindications section carries an unusual passage: the pregnancy exclusion is followed by a suggestion to substitute a cognitive support peptide, which reads as boilerplate rather than clinical guidance given the target population.
Presentation: 20 mg lyophilised vial reconstituted with bacteriostatic water, subcutaneous, 30–60 day courses repeated 3–4 times per year.
What it does
The core action is on prostate tissue: normalising how prostate cells behave and maintaining the structure of the gland, with protective effects against the degenerative changes that come with age.
On inflammation: it reduces inflammation in prostate tissue, and reduces the risk of chronic prostatitis — long-running inflammation of the prostate — and of repeated inflammatory episodes.
On urinary function: it improves urinary flow and reduces the discomfort that comes with urinary retention, meaning difficulty emptying the bladder fully.
On secretion and reproduction: it maintains the prostate's proper secretory function — its production of fluid — improves semen quality and male reproductive function generally, improves measures of male fertility, and is said to produce better ejaculations.
On protection and recovery: it guards prostate tissue against oxidative damage, which is the wear caused by reactive molecules, and helps tissue recover after infections or long-term stress. It is also linked to the pelvic floor, the sheet of muscle supporting the bladder and bowel.
Looking further ahead, it is described as reducing the likelihood of prostate problems later in life.
Tissue-level: normalisation of prostate cell activity with maintenance of tissue structure; protective effect against age-related degenerative change in prostatic tissue; protection against oxidative damage.
Inflammatory: reduction of inflammation in prostate tissue; reduced risk of chronic prostatitis and recurrent prostatic inflammatory episodes.
Urinary: improved urinary flow; reduced discomfort associated with urinary retention.
Secretory and reproductive: maintenance of proper prostatic secretory function; improved semen quality and general male reproductive function; improved male fertility parameters; improved ejaculation.
Recovery: tissue recovery following infection or long-term stressors, with the pelvic floor named alongside oxidative protection.
Preventative: reduced likelihood of prostate dysfunction later in life; support for structure, function, and health of the prostate particularly in ageing men and in chronic prostatic conditions.
The indication set is coherent and confined to one organ system throughout, which is unusual among the bioregulator pages on this site — most spread into systemic longevity claims. This one does not, and the tighter scope is worth noting in its favour. What it lacks is any distinction between symptomatic effect and structural change: improved urinary flow and reduced prostate dysfunction later in life are listed in the same register, and no data are available for either.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Supports prostate gland function in ageing men.Anecdotal
- Addresses an enlarged prostate that is not cancer, by easing common symptoms such as needing to urinate more often.Anecdotal
- Helps normalise male reproductive and sexual health.Anecdotal
- Helps restore urinary function affected by prostate enlargement.Anecdotal
- Supports the structure, function, and health of the prostate, especially in ageing men and those with long-running prostate conditions.Anecdotal
- Normalises prostate cell activity and maintains the structure of the tissue.Anecdotal
- Reduces the risk of long-running prostate inflammation and repeated inflammatory episodes.Anecdotal
- Reduces inflammation in prostate tissue.Anecdotal
- Maintains the prostate's proper production of fluid.Anecdotal
- Improves urinary flow and reduces the discomfort of not being able to empty the bladder fully.Anecdotal
- Produces better ejaculations.Anecdotal
- Improves semen quality and male reproductive function generally.Anecdotal
- Offers protective effects against age-related degenerative change in prostate tissue.Anecdotal
- Reduces the likelihood of prostate problems later in life.Anecdotal
- Improves measures of male fertility.Anecdotal
- Helps tissue recover after infections or long-term stress.Anecdotal
- Protects against oxidative damage in prostate tissue, and supports the pelvic floor — the sheet of muscle supporting the bladder and bowel.Anecdotal
- Supports prostate gland function in ageing men.Anecdotal
- Addresses benign prostatic hyperplasia by mitigating common symptoms including increased urinary frequency.Anecdotal
- Helps normalise male reproductive and sexual health.Anecdotal
- Helps restore urinary function related to prostatic enlargement.Anecdotal
- Supports the structure, function, and health of the prostate, particularly in ageing men and chronic prostatic conditions.Anecdotal
- Normalises prostate cell activity and maintains tissue structure.Anecdotal
- Reduces risk of chronic prostatitis and recurrent prostatic inflammation.Anecdotal
- Reduces inflammation in prostate tissue.Anecdotal
- Maintains proper prostatic secretory function.Anecdotal
- Improves urinary flow; reduces discomfort associated with urinary retention.Anecdotal
- Improved ejaculation.Anecdotal
- Improves semen quality and general male reproductive function.Anecdotal
- Protective effect against age-related degenerative change in prostatic tissue.Anecdotal
- Reduces likelihood of prostate dysfunction later in life.Anecdotal
- Improves male fertility parameters.Anecdotal
- Supports tissue recovery following infection or long-term stressors.Anecdotal
- Protects against oxidative damage in prostatic tissue; decreased pelvic floor tension is also named in this context.Anecdotal
Reconstitution and dosing
The vial holds 20 milligrams (mg). Mix it with 2 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 200 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake.
With 20 mg in 2 mL, every unit on the syringe holds 100 micrograms. So 2 milligrams is 20 units exactly. The other dose is 750 micrograms, which works out at 7.5 units; round up to 8, a mark you can actually see on the syringe. The difference is about 6%.
Inject under the skin, once a day.
There are two protocols and neither ramps up or down — the dose is flat throughout. The standard protocol is 750 micrograms a day for 30 to 60 days. The maximum protocol is 2 milligrams a day for the same length of time, and it is specifically for people with severe prostate enlargement, or those struggling with frequent urination, reduced pelvic floor tension, or painful or minimal ejaculation.
Repeat three or four times a year.
No best time of day to dose has been established, and there are no food rules.
These are long courses by the standards of the other bioregulators on this site — 30 to 60 days of daily dosing, against 10 or 20 days for most of them — so the total amount is much larger. A 60-day course at the maximum dose is 120 milligrams, or six vials.
Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL — 100 mcg per insulin unit. Both protocols use the same diluent volume. Add down the vial wall and swirl; do not shake.
Recomputed draws: 750 mcg = 7.5 units (drawn as 8), a 6.3% divergence from syringe-mark rounding; 2 mg = 20 units, exact. Nothing above 10%.
Administration: subcutaneous, once daily. Dose flat in both protocols with no titration; the protocols differ only in dose level.
Standard protocol: 750 mcg daily for 30–60 days. Maximum protocol: 2 mg daily for 30–60 days, for a specified population — severe benign prostatic hyperplasia, or those contending with urinary frequency, decreased pelvic floor tension, or painful or minimal ejaculation. That is unusually specific indication-matching for these pages; there is still no criterion for escalating from one protocol to the other mid-course.
Cycle: 30–60 days, repeated 3–4 times per year.
No dosing time and no meal relationship are stated.
Exposure is the largest among the bioregulators on this site. Standard protocol: 22.5–45 mg per course, roughly one to two vials. Maximum protocol: 60–120 mg per course, three to six vials. At 3–4 cycles annually the maximum protocol reaches up to 480 mg per year, against 40–60 mg for the 10-day-cycle bioregulators here. There is no cumulative exposure guidance and no rationale for the much longer course length.
20 mg vial — standard protocol
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit.
10 mg/mL · 100 mcg per unit
Cycle: 30–60 days; recommended 3–4 times per year · Frequency: 1×/day, daily; subcutaneous. No dosing time or relationship to meals has been specified
| When | Dose | Draw | How often |
|---|---|---|---|
| Daily for 30–60 days (750 mcg — drawn as 8 units, computed 7.5) | 750 mcg | 7.5 units | 1×/day |
20 mg vial — maximum protocol (severe BPH, urinary frequency, decreased pelvic floor tension, or painful/minimal ejaculation)
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit. A 60-day course at this dose uses six vials.
10 mg/mL · 100 mcg per unit
Cycle: 30–60 days; recommended 3–4 times per year · Frequency: 1×/day, daily; subcutaneous. No dosing time or relationship to meals has been specified
| When | Dose | Draw | How often |
|---|---|---|---|
| Daily for 30–60 days (2 mg) | 2 mg | 20 units | 1×/day |
20 mg in 2 mL is 10 mg/mL, or 100 mcg per unit. Draw 7.5 units (0.075 mL) for 750 mcg.
Who should avoid it
- Anyone with prostate cancer. The reasoning is worth knowing: cytomedin peptides are not recommended when there is an active cancer, because stimulating protein production could in theory encourage a tumour to grow. This idea has never been tested in a clinical trial.
- Anyone who turns out to be allergic to this product or anything associated with it should stop using it.
- Anyone pregnant or nursing. This exclusion sits oddly on a compound for the prostate and appears to be a general caution rather than advice specific to Prostamax, but it is kept here so the list is complete.
- Take care if you are on **androgen therapy** — testosterone or a related hormone treatment — or on prostate medications. The effects may be amplified or overlap. Prostate medicines are usually prescribed and monitored, so this is one to raise with the prescriber rather than manage alone.
- Take care when combining with other bioregulators. Testoluten, for the testes, and Ventfort, for blood vessels, are named as compounds that may be synergistic with Prostamax in male reproductive protocols. This is framed positively, but combining bioregulators still means combining effects, and neither of those has a page on this site.
- No minimum age has been established, and no guidance exists on checking prostate health before starting. For a compound whose main exclusion is prostate cancer, and whose symptoms overlap with it, an assessment first is worth raising with a doctor.
- Talk to a doctor before starting, and go through your full medication list with them.
- Prostate cancer: cytomedin peptides are stated as not recommended in the presence of active malignancy, on the theoretical basis that stimulation of protein synthesis could promote tumour growth. This hypothesis has never been studied in clinical trials, which cuts both ways: the risk is unquantified rather than excluded.
- Hypersensitivity: discontinue on discovering allergy to the product or associated components.
- Pregnancy and nursing: contraindicated. Included for completeness; this is a general caution rather than considered guidance for this indication.
- Androgen therapy and prostate medications: effects may be amplified or overlap; use caution. This is an interaction rather than a side effect and is placed here accordingly. Relevant to anyone on 5-alpha reductase inhibitors, alpha blockers, or testosterone replacement, all of which are prescriber-monitored.
- Other bioregulators: Testoluten (testes) and Ventfort (vasculature) are named as potentially synergistic in male reproductive protocols. Framed positively, but it is still combined bioregulator exposure and neither has a page on this site.
- No baseline prostate assessment has been established despite active malignancy being the principal exclusion and the symptom sets overlapping substantially. No PSA or examination guidance exists, and no age floor has been established.
Side effects
- Reactions where you inject — redness, swelling, itching, or a **histamine response**, meaning the flare and itch the body produces when it reacts to something.
- That is the entire list of known side effects. Two further cautions about combining Prostamax with other things are interactions and appear in the section above.
- No monitoring has been established for a compound taken daily for up to 60 days, and there is no guidance on reasons to stop other than an allergic reaction.
- Given the effects claimed on urinary flow and ejaculation, any change in either direction is worth tracking, though no guidance on it is available.
- Injection site reactions: erythema, swelling, pruritus, histamine responses.
- That is the complete adverse effect list. The two interaction cautions — androgen therapy and prostate medications, and bioregulator synergy — are handled in the avoidance section rather than listed as adverse effects.
- No monitoring parameters have been established for a 30–60 day daily course, and there are no discontinuation criteria beyond hypersensitivity.
- No adverse effect has been documented for the urinary or ejaculatory function Prostamax is claimed to modify, in either direction.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
- Testoluten
Named as possibly working well with Prostamax in male reproductive protocols. It is a bioregulator for the testes. There is no page for it on this site, and no dosing guidance exists for the combination.
Named as a bioregulator for the testes potentially complementary in male reproductive protocols. No page exists for it on this site, and no combined schedule, dose adjustment, or monitoring guidance is given.
- Ventfort
The other bioregulator named as potentially synergistic — this one acts on blood vessels. Again there is no page for it on this site and no dosing guidance for combining it.
Named alongside Testoluten as a vascular bioregulator potentially synergistic in male reproductive protocols. No page on this site, no combined guidance.
- Androgen therapy and prostate medications — named, but as a caution
Included as a caution, not as a recommendation. Effects may be amplified or overlap when Prostamax is used alongside testosterone or prostate medicines. Those are prescribed and monitored treatments, so raise it with whoever prescribes them.
An interaction caution — amplified or overlapping effects with androgen therapy or prostate pharmacotherapy. Listed here because it is the combination most likely to arise in the target population and because the relevant agents are prescriber-managed.
Dosing figures have been reviewed and units are recomputed from the stated protocol.